In a nutshell The study compared outcomes of utidelone plus capecitabine (Xeloda) versus capecitabine (C) alone in previously treated patients with anthracycline- and taxane-resistant metastatic breast cancer (MBC). The authors found that this combination improved survival compared to C alone in such patients. Some background...
Read More
In a nutshell This study compared the effectiveness of FOLFIRI (5-fluorouracil, folinic acid, and irinotecan) with either cetuximab (Erbitux) or bevacizumab (Avastin) in the treatment of advanced colorectal cancer (CRC). Researchers suggested that FOLFIRI with cetuximab resulted in improved response and longer survival for these patients. Some...
Read More
In a nutshell This trial is being carried out to assess the safety and effectiveness of an experimental drug called BCA101 alone and in combination with pembrolizumab (Keytruda) in advanced solid tumors that are EGFR-positive. The main outcomes to be measured are the occurrence of side effects and response to treatment. The details Advanced solid...
Read More
In a nutshell This trial is being carried out to assess the safety and effectiveness of an experimental drug called BCA101 alone and in combination with pembrolizumab (Keytruda) in advanced solid tumors that are EGFR-positive. The main outcomes to be measured are the occurrence of side effects and response to treatment. The details Advanced...
Read More
In a nutshell This study is looking to trial the addition of a new form of vaccine called a neoantigen vaccine in combination with nab–paclitaxel (Abraxane), duvalumab (Imfinzi), and tremelimumab (CP-675,206), in patients with metastatic triple-negative breast cancer (mTNBC). The main outcome that will be measured is survival without the...
Read More
In a nutshell This study looked at patients with melanoma which had spread to the bones. They found that targeted bone treatments can reduce the risk of broken bones and other complications in these patients. Some background Melanoma spreads to the bones in 11-18% of patients. Cancer which has spread to the bone is called bone metastases...
Read More
In a nutshell This study compared nivolumab (Opdivo) and ipilimumab (Yervoy) for treating advanced melanoma that has been surgically removed. They found that patients treated with nivolumab survived cancer-free for longer than patients treated with ipilimumab. Some background Melanoma which has spread to the lymph nodes or other organs is...
Read More
In a nutshell This study compared the effectiveness of three different treatments for metastatic (spread to other parts of the body) colorectal cancer (mCRC). Researchers suggested that fruquintinib (Elunate) was associated with the best treatment outcomes. Some background Colorectal cancer is a common cancer worldwide and 25% of patients present with...
Read More
In a nutshell This study was carried out to assess whether immune related side effects (IRSE) of anti-PD1 therapy affect the survival of patients with advanced melanoma. The authors of this study found that patients who had IRSE had better outcomes. Some background Advanced melanoma is a form of skin cancer that comes from a cell called a...
Read More
In a nutshell This study compared the survival outcomes of different chemotherapy treatments in patients with inoperable advanced colorectal cancer (CRC). Researchers suggested that FOLFOXIRI plus bevacizumab (Avastin) significantly improved the survival of these patients. Some background Around 20% of patients present with advanced CRC at diagnosis....
Read More
In a nutshell This trial compared the effectiveness of neratinib (Nerlynx) plus capecitabine (Xeloda) in treating metastatic breast cancer compared to lapatinib (Tykerb) plus capecitabine in patients who have received 2 or more treatment lines. The authors found that neratinib plus capecitabine (N+C) resulted...
Read More
In a nutshell This phase 2 trial will investigate the safety of experimental treatment zanidatamab (ZW25) in combination with palbociclib (Ibrance) and fulvestrant (Faslodex) in patients with advanced breast cancer (BC). The main outcomes evaluated will be the rate of side effects and survival without cancer worsening. This trial is...
Read More
